Pulse Biosciences had a productive Q4 2025, with total revenue reaching $264 thousand, an increase from the previous quarter. The company advanced its nsPFA platform into late-stage clinical development for atrial fibrillation and surgical cardiac ablation, receiving FDA IDE approvals for pivotal studies. GAAP net loss for the quarter was ($17.4) million, an improvement from the prior year, while non-GAAP net loss was ($12.2) million.

Pulse Biosciences posted a GAAP net loss of $19.2M in Q2 2025, with no revenue reported and increased spending in R&D and G&A. The company ended the quarter with over $106M in cash.

Pulse Biosciences reported a net loss of $16.795 million for Q1 2025, an increase from $10.137 million in Q1 2024. Total costs and expenses increased significantly, driven by non-cash stock-based compensation and administrative expenses. The company is advancing its nsPFA technology with several clinical trials and commercialization efforts.

In Q4 2024, Pulse Biosciences posted a GAAP net loss of $19.4 million and a non-GAAP net loss of $10.4 million. The company had no revenue, and costs rose due to expansion activities and stock-based compensation. The company ended the quarter with strong liquidity following a successful warrant exercise.

Pulse Biosciences reported a GAAP net loss of $12.7 million for the third quarter of 2024, compared to a net loss of $10.6 million for the same period in 2023. The company's cash and cash equivalents totaled $79.0 million as of September 30, 2024, which includes $60 million in gross proceeds from a rights offering that closed in July 2024.

Pulse Biosciences announced business updates and preliminary financial results for the second quarter ended June 30, 2024. Key milestones included completing the first soft tissue ablation procedures in the U.S., the first epicardial ablations in Europe, and expanding enrollment of the endocardial ablation study. Total GAAP costs and expenses were $11.7 million, while non-GAAP costs and expenses were $9.4 million. Cash and cash equivalents totaled $26.2 million as of June 30, 2024, not including $60 million in proceeds from a rights offering that closed in July 2024.

Pulse Biosciences reported a GAAP net loss of $10.1 million for the first quarter of 2024, compared to a $9.8 million loss in the same period last year. Cash and cash equivalents totaled $34.9 million as of March 31, 2024. The company is focused on advancing its CellFX nsPFA technology and executing its percutaneous electrode pilot program.

Pulse Biosciences reported a GAAP net loss of ($11.9) million for Q4 2023, compared to ($9.2) million for Q4 2022. Total GAAP costs and expenses were $12.5 million, up from $8.7 million in the prior year period. Cash and cash equivalents totaled $44.4 million as of December 31, 2023.

Pulse Biosciences reported a GAAP net loss of $10.6 million for the third quarter of 2023, compared to a $18.0 million loss in the same period of the previous year. The company's cash and cash equivalents totaled $50.4 million as of September 30, 2023. They are on track to file a 510(k) submission for clearance for their cardiac ablation clamp and initiate the cardiac ablation catheter first-in-human study between December 2023 and end of first quarter 2024.

Pulse Biosciences reported a GAAP net loss of $9.9 million for the three months ended June 30, 2023, compared to a $14.0 million loss for the same period in the prior year. Cash and cash equivalents totaled $58.7 million as of June 30, 2023.

Pulse Biosciences reported a GAAP net loss of $9.8 million for the first quarter of 2023, compared to a $17.3 million loss in the prior year period. Cash and cash equivalents totaled $54.1 million as of March 31, 2023. The company advanced its preclinical and regulatory objectives for its two novel nsPFA devices.

Pulse Biosciences reported no revenue for Q4 2022 due to the discontinuation of commercial dermatology activity. The company reduced its cash usage and is focusing on advancing its nsPFA technology for electrophysiology and atrial fibrillation treatment.

Pulse Biosciences reported no revenue for the third quarter of 2022. The company is focusing on cardiac cellular/tissue ablation for atrial fibrillation treatment and secured a $65 million term loan. They anticipate a quarterly cash burn rate of approximately $8 million commencing in Q1 2023.

Pulse Biosciences reported revenue of $265 thousand for the second quarter of 2022. The company's GAAP net loss was $14.0 million, while non-GAAP net loss was $11.9 million. They transitioned their commercial focus toward driving utilization of CellFX Systems in a select group of dermatology clinics.

Pulse Biosciences reported first quarter 2022 revenue of $444 thousand. The company is prioritizing increasing CellFX System utilization at a subset of commercial clinics to establish commercial integration best practices.

Pulse Biosciences reported fourth quarter revenue of $844 thousand and full year revenue of $1.4 million. The company is focusing on increasing commercial clinic utilization and reducing emphasis on new system sales.

Pulse Biosciences reported its Q3 2021 financial results, achieving revenue for the first time with $574 thousand. The company is focusing on clinical studies to expand the CellFX System's indications and is conducting preclinical work across other medical specialties.

Pulse Biosciences reported a GAAP net loss of $15.3 million for the second quarter of 2021, compared to a net loss of $11.3 million for the same period in 2020. Cash, cash equivalents and investments totaled $47.4 million as of June 30, 2021, compared to $59.9 million as of March 31, 2021. The company onboarded 34 controlled launch participant clinics across the U.S., Europe and Canada.

Pulse Biosciences reported a GAAP net loss of $18.6 million for the first quarter of 2021, compared to a net loss of $11.9 million for the same period in the prior year. The company's cash, cash equivalents and investments totaled $59.9 million as of March 31, 2021, compared to $20.5 million as of December 31, 2020. The company onboarded the first 15 participating U.S. and European aesthetic specialty practices in the first quarter for CellFX® System Controlled Launch program.

Pulse Biosciences reported financial results for Q4 and full year 2020, with operating expenses at $13.8 million and a net loss of ($13.8) million for the quarter. The company's cash, cash equivalents and investments totaled $20.5 million as of December 31, 2020.

Pulse Biosciences reported a net loss of $12.9 million for the third quarter of 2020. The company's cash, cash equivalents, and investments totaled $29.6 million as of September 30, 2020. They are on track to potentially receive marketing clearances for CellFX System in the United States, Canada, and the European Union by the end of the first quarter of 2021.

Pulse Biosciences reported a net loss of $11.3 million for the second quarter of 2020. The company's cash, cash equivalents and investments totaled $37.8 million as of June 30, 2020, compared to $15.9 million as of March 31, 2020. The $30.0 million rights offering generated $29.5 million of net proceeds.

Pulse Biosciences reported a net loss of $11.9 million for Q1 2020, compared to $10.1 million for Q1 2019. Operating expenses increased due to the expansion of operational infrastructure, marketing and sales functions, research and development teams, and clinical trial costs. The company's cash, cash equivalents, and investments totaled $15.9 million as of March 31, 2020.

Pulse Biosciences reported a net loss of $13.8 million for the fourth quarter ended December 31, 2019. The company's cash, cash equivalents, and investments totaled $25.4 million as of December 31, 2019. Operating expenses for the quarter were $13.9 million.